Anchor Therapeutics has filed multiple patent applications related to its pepducin technology throughout the world. These patent applications provide the foundation for future drug development. Broad coverage for pepducins is also provided by exclusively licensed US patent numbers 6,864,229 and 7,696,168, and their international counterparts. Anchor is actively expanding intellectual property protection for its technology in filings with broad patent claims for composition of matter, methods of use, formulations and combination uses for a variety of GPCR targets and related technology.